Axsome Therapeutics (AXSM)
156.31
0.00 (0.00%)
Upcoming Events
Latest Headlines
Mizuho on Axsome Therapeutics (AXSM): 'recommend buying ahead of AXSM's 3Q print'
October 21, 2026 5:26 AM - StreetInsider
RBC Capital Defending Axsome Therapeutics (AXSM): 'we would be buyers at these levels'
October 14, 2026 5:58 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Lowered to $295 at RBC Capital
October 8, 2026 8:27 AM - StreetInsider
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
October 7, 2026 7:00 AM - StreetInsider
3 high-conviction SMID-cap biotech stocks to buy: Jefferies
October 1, 2026 3:00 PM - StreetInsider
Wells Fargo names 13 stocks as overweight tactical ideas
October 1, 2026 6:30 AM - StreetInsider
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
September 30, 2026 3:35 PM - StreetInsider
Axsome Therapeutics (AXSM) PT Lowered to $247 at Morgan Stanley
September 25, 2026 8:27 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
September 25, 2026 6:46 AM - StreetInsider
Truist Securities Starts Axsome Therapeutics (AXSM) at Buy
September 23, 2026 5:03 AM - StreetInsider
Survey finds Alzheimer's agitation often goes unrecognized until daily disruption
September 21, 2026 7:02 AM - StreetInsider
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s
September 21, 2026 7:00 AM - StreetInsider
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
September 17, 2026 7:00 AM - StreetInsider
Axsome Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2026 7:00 AM - StreetInsider
Axsome begins Phase 3 trial of AXS-05 for smoking cessation
August 31, 2026 7:00 AM - StreetInsider
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
August 31, 2026 7:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
August 24, 2026 6:45 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $316 at Mizuho
August 12, 2026 6:36 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $251 at Morgan Stanley
August 11, 2026 9:08 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Lowered to $279 at RBC Capital
August 11, 2026 7:57 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $268 at Needham
August 11, 2026 7:10 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $256 at Wells Fargo
August 11, 2026 6:54 AM - StreetInsider
Axsome Therapeutics (AXSM) PT Raised to $275 at Guggenheim
August 11, 2026 6:45 AM - StreetInsider
Form 10-Q Axsome Therapeutics, For: Jun 30
August 10, 2026 4:08 PM - SEC Filing
Axsome Therapeutics (AXSM) Misses Q2 EPS by 14c
August 10, 2026 7:39 AM - StreetInsider
Form 8-K Axsome Therapeutics, For: Aug 10
August 10, 2026 7:06 AM - SEC Filing
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 10, 2026 7:00 AM - StreetInsider
Form 4 Axsome Therapeutics, For: Aug 05 Filed by: TABUTEAU HERRIOT
August 7, 2026 7:00 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: TABUTEAU HERRIOT
August 6, 2026 5:09 PM - SEC Filing
Form 144 Axsome Therapeutics, Filed by: TABUTEAU HERRIOT
August 5, 2026 6:04 PM - SEC Filing
Axsome Therapeutics (AXSM) PT Lowered to $306 at Mizuho
July 31, 2026 6:53 AM - StreetInsider
Form SCHEDULE 13G/A Axsome Therapeutics, Filed by: BlackRock, Inc.
July 27, 2026 4:26 PM - SEC Filing
Full Article List
